Background: Increased carotid restenosis due to revascularization therapy is associated with insulin resistance. We hypothesize that glucose control using acarbose may attenuate intimal hyperplasia in rat carotid endarterectomy model of diet-induced insulin resistance. Methods: Rats were fed low-fat complex carbohydrate (control) or high-fat sucrose (insulin resistance) for 4 months. Three days preoperatively, some high-fat-sucrose rats were on acarbose, remainder of the rats received placebo. Rat carotids were assessed with duplex pre-and postoperatively. Acarbose and placebo continued for 2 weeks. Glucose, insulin, blood flow velocities and intimal hyperplasia were determined. Results: High-fat sucrose plus acarbose attenuated intimal hyperplasia. Post-drug high-fat sucrose glucose decreased. Blood flow velocities postoperatively elevated above baseline. High-fat sucrose increased blood flow velocities postoperatively, which was attenuated with acarbose. Conclusion: Glucose control by acarbose in rat carotid endarterectomy model of diet-induced insulin resistance resulted in attenuation of intimal hyperplasia.
Sdringola S. , Assali A., Anderson H., Smalling RWRestenosis: relationship with thrombosis. Curr Intern Cardiol Rep. 2000; 2(4):285-292.
2.
Jawien A., Bowen-Pope D., Lindner V., Schwartz SM, Clowes AWPlatelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest . 1992;89(2):507-511.
3.
Berceli SA, Jiang Z., Klingman NV, et al. Differential expression and activity of matrix metalloproteinases during flow-modulated vein graft remodeling. J Vasc Surg. 2004;39(5):1084-1090.
4.
Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of Platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation . 1999;100(25): 2477-2484.
5.
McNeill AM, Rosamond WD, Girman CJ, et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol. 2004;94(10):1249-1254.
6.
Kornowski R. , Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation. 1997 ;95(6):1366-1369.
7.
Yamagishi S. , Imaizumi T.Diabetic Vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005;11(18):2279-2299.
8.
Piatti P., Mario C., Monti LD, et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation. 2003;108(17):2074-2081.
9.
Hanefeld M., Schaper F., Koehler C., et al. Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study. Horm Metab Res.2009; 41(2):132-136.
10.
McNamara DB , Murthy SN, Fonseca AN, Desouza CV, Kadowitz PJ, Fonseca VAAnimal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention. Can J Physiol Pharmacol.2009 ; 87(1):37-50.
11.
Zeymer U.Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes. Int J Cardiol. 2006; 107(1):11-20.
12.
Godbout A., Chiasson JLWho should benefit from the use of alpha-glucosidase inhibitors? Curr Diab Rep. 2007;7(5): 333-339.
13.
Fischer S., Patzak A., Rietzsch H., et al. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obes Metab . 2003;5(1):38-44.
14.
Azuma K., Toyofuku Y., Iesaki T., et al. Acarbose, an α-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation . Biochem Biophy Res Commun. 2006;345(2):688-693.
15.
Yamagishi S., Matsui T., Ueda S., Fukami K., Okuda S.Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders. Curr Drug Metab.2009;10(2):159-163.
16.
Hanefeld M. , Schaper F.Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther. 2008;6(2):153-163.
17.
Hanefeld M. , Chiasson JL, Koehler C., Henkel E., Schaper F., Kurttschiev TTAcabose slows progression of intimal-media thickness of the carotid arteries in subjects with impaired glucose tolerance . Stroke. 2004;35(5):1073-1078.
18.
Chiasson JL , Josse RG, Gomis R., Hanefeld M., Karasik A., Laakso M.Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486-494.
19.
Yamagishi S. , Nakamura K., Takeuchi M.Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome. Med Hypotheses. 2005;65(1):152-154.
20.
Shimabukuro M., Higa N., Chinen I., Yamakawa K., Takasu N.Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab. 2006;91(3):837-842.
21.
Ridray S.Hyperinsulinemia and smooth muscle cell proliferation. Int J Obes Relat Metab Disord. 1995;19(suppl 1):S39-S51.
22.
Brown AT, Smith TP, Cruz CP, et al. Intimal hyperplasia following carotid endarterectomy in an insulin-resistant rat model. Metabolism. 2003;52(7):834-839.
23.
Southern FN , Cruz N., Fink LM, et al. Hyperhomocysteinemia increases intimal hyperplasia in a rat carotid endarterectomy model. J Vasc Surg. 1998;28(5):909-918.
24.
Bledsoe SL, Barr JC, Fitzgerald RT, et al. Pravastatin and clopidogrel combined inhibit intimal hyperplasia in a rat carotid endarterectomy model. Vasc Endovasc Surg . 2006; 40(1):49-57.
25.
Brown AT, Chen H., Davis JA, et al. Plasma homocysteine measurements after carotid artery manipulation and clamping in a rat CEA model. J Vasc Surg. 2004;40(4):796-803.
26.
Davis JA, Brown AT, Chen H., et al. Cigarette smoke increases intimal hyperplasia and homocysteine in a rat carotid endarterectomy. J Surg Res. 2004;121(1):69-75.
27.
Cruz CP, Eidt J., Drouilhet J., et al. Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model. J Vasc Surg. 2001;34(4):724-729.
28.
Kalapatapu VR, Satterfield L., Brown AT, et al. The effects of Toradol on postoperative intimal hyperplasia in a rat carotid endarterectomy model: laboratory research . Vasc Endovascular Surg. 2007;41(5):402-408.
29.
Bledsoe SL, Brown AT, Davis JA, Chen H., Eidt JF, Moursi MMEffect of clopidogrel on platelet aggregation and intimal hyperplasia following carotid endarterectomy in the rat. Vascular. 2005;13(1):43-49.
30.
Balfour JA, McTavis D.Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus . Drugs. 1993;46(6): 1025-1054.
31.
Bavenholm PN , Efendic S.Postprandial hyperglycaemia and vascular damage-the benefits of acarbose. Diabetes Vasc Dis Res. 2006;3(2):72-79.
32.
Aronson D., Bloomgarden Z., Rayfield EJPotential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol. 1996;27(3):528-535.
33.
Tsunosue M. , Mashiko N., Ohta Y., et al. An α-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med. 2010;10(2):139-141.
34.
Park SH, Marso SP, Zhou Z., Foroudi F., Topol EJ, Lincoff M.Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation. 2001;104(7):815-819.
35.
Sato T., Iwaki M., Shimogaito N., Wu X., Yamagishi S., Takeuchi M.TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med. 2006;6(3):351-358.
36.
Vallejo S., Angulo J., Peiro C., et al. Treatment with acarbose may improve endothelial dysfunction in streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol . 2000;36(2):256-262.
37.
Ceriello A. , Mercuri F., Quagliaro L., et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia . 2001;44(7):834-838.
38.
Schiekofer S., Andrassy M., Chen J., et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MARK, and nuclear factor kappaB in PBMCs. Diabetes. 2003;52(3):621-633.
